We found a significant relationship between insulin resistance and sympathetic response to moxonidine, suggesting large clinical trials are needed to evaluate the effectiveness of this medication potentially targeting the most insulin resistant PCOS cases. This evidence concerns the gene INS and polycystic ovary syndrome.